Fermenta Biotech Ltd (506414) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 506414 | NSE: | Pharmaceuticals & Drugs | Small Cap

Fermenta Biotech Share Price

270 5.45 2.06%
as on 05-Dec'25 15:23

Fermenta Biotech Ltd (506414) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 506414 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Fermenta Biotech

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Fermenta Biotech stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
8.17
Market Cap:
778.6 Cr.
52-wk low:
219
52-wk high:
449

Is Fermenta Biotech Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Fermenta Biotech: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Fermenta Biotech Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -5.5%-8.5%-7.5%43.5%13.8%14.5%9.9%-6.2%2.6%19.1%-
Value Creation
Index
-1.4-1.6-1.52.10.00.0-0.3-1.4-0.80.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 6.15.512.5405301373388329307431494
Sales YoY Gr.--10.1%126.6%3,134.8%-25.7%24.1%4.1%-15.2%-6.6%40.2%-
Adj EPS -3.3-6.6-7.24221.817.79.6-10.3-4.622.832.4
YoY Gr.-NANANA-48.1%-18.8%-46.1%-208.3%NANA-
BVPS (₹) 3032.623.586.7106.3124.3132.2111.9104.4130.2136.8
Adj Net
Profit
-9.1-18.3-19.911662.951.127.6-29.8-13.166.695
Cash Flow from Ops. -5-9.11.390.529.86350.412410533.8-
Debt/CF from Ops. -11-4.9107.92.37.43.64.71.81.33.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 60.4%7.5%3.5%40.2%
Adj EPS NA0.9%33.7%NA
BVPS17.7%4.1%-0.5%24.7%
Share Price 16.2% -3.5% 13.5% -34.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-10.3-21.2-25.873.622.4157.2-8.2-419.224.3
Op. Profit
Mgn %
-98.9-154-26.535.52325.719.812.112.324.326
Net Profit
Mgn %
-147.6-331.3-159.228.620.913.77.1-9.1-4.315.519.3
Debt to
Equity
0.70.52.20.90.70.60.60.70.40.30
Working Cap
Days
8661,020520111304308355383320245123
Cash Conv.
Cycle
-24-16-20351291411681711178843

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Fermenta Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) 32.4 38.1
TTM Sales (₹ Cr.) 494 563
BVPS (₹.) 136.8 132.8
Reserves (₹ Cr.) 388 376
P/BV 1.93 1.99
PE 8.17 6.95
From the Market
52 Week Low / High (₹) 219.00 / 449.00
All Time Low / High (₹) 4.90 / 449.00
Market Cap (₹ Cr.) 779
Equity (₹ Cr.) 14.7
Face Value (₹) 5
Industry PE 40.7

Management X-Ray of Fermenta Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Fermenta Biotech - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Fermenta Biotech

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales6613405301373388329307431
Operating Expenses 131424277232278311290270331
Manufacturing Costs24641344455505368
Material Costs0009283124144126105139
Employee Cost 56653505759545460
Other Costs 651290655353605764
Operating Profit -7-9-111286995773937100
Operating Profit Margin (%) -108.0%-154.0%-90.1%31.6%22.8%25.4%19.8%11.9%12.2%23.2%
Other Income 1122614788813
Interest 261121201918211715
Depreciation 23412151924242423
Exceptional Items 0000000-60-90
Profit Before Tax -9-18-23121486343-58-574
Tax -00111-161112-1147
Profit After Tax -9-18-24110645230-57-1968
PAT Margin (%) -148.0%-331.0%-193.0%27.3%21.2%13.9%7.8%-17.3%-6.1%15.7%
Adjusted EPS (₹)-3.3-6.7-8.840.122.118.010.5-19.8-6.523.2
Dividend Payout Ratio (%)-6%-3%-2%1%23%14%12%-6%-19%11%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 839065249307358381323301380
Share Capital 2225141414141415
Reserves 808762244292344367308287365
Minority Interest0000000000
Debt173813819520620721218511096
Long Term Debt1434132135102110115844315
Short Term Debt2466010496971016781
Trade Payables11243474646525364
Others Liabilities 4917184412108123107109101
Total Liabilities 149146223532572719762667573641

Fixed Assets

Gross Block100913128163315293320377358
Accumulated Depreciation6122437657392116135
Net Fixed Assets 94812104126250220228261223
CWIP 1102271573545216
Investments 4131108767213131544
Inventories000881141331301107994
Trade Receivables0006677961186777120
Cash Equivalents 31291324131555762
Others Assets 12104100877913021614694122
Total Assets 149146223532572719762667573641

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -5-919130635012410534
PBT -9-18-23121486343-58-574
Adjustment 41020393440391478540
Changes in Working Capital 1-25-36-38-27-223123-78
Tax Paid -11-1-33-14-13-941-3
Cash Flow From Investing Activity -820-89-97-39-44-32-64-150
Capex -21-8-4-35-64-55-37-40-19-3
Net Investments 1326-84-532424-164-5
Others -02-1-9191-7-08
Cash Flow From Financing Activity 14-138812-48-1-22-41-91-51
Net Proceeds from Shares 0000000002
Net Proceeds from Borrowing 14006-34143-18-47-33
Interest Paid -2-6-9-20-21-18-17-20-17-12
Dividend Paid -1-1-1-1-60-7-4-4-4
Others 2-69828132-11-23-4
Net Cash Flow 1-216-5718-419-1-17

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-10.44-21.25-31.372.7823.3615.638.18-16.19-619.85
ROCE (%)-5.46-8.47-7.5243.4613.8314.549.85-6.182.5619.07
Asset Turnover Ratio0.040.040.071.070.540.580.520.460.50.71
PAT to CFO Conversion(x)N/AN/AN/A0.830.471.211.67N/AN/A0.5
Working Capital Days
Receivable Days614103087851011038684
Inventory Days0007912212112313311273
Payable Days00090200137116141182154

Fermenta Biotech Ltd Stock News

Fermenta Biotech Ltd FAQs

The current trading price of Fermenta Biotech on 05-Dec-2025 15:23 is ₹270.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Fermenta Biotech stood at ₹778.6.
The latest P/E ratio of Fermenta Biotech as of 04-Dec-2025 is 8.17.
The latest P/B ratio of Fermenta Biotech as of 04-Dec-2025 is 1.93.
The 52-week high of Fermenta Biotech is ₹449.0 and the 52-week low is ₹219.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fermenta Biotech is ₹494.4 ( Cr.) .

About Fermenta Biotech Ltd

Fermenta Biotech an established enterprise with a rich seven-decade history, operates across diverse sectors, including pharmaceuticals, animal feed, nutrition, integrated biotech, environmental solutions and real estate. A key focal point of the company’s expertise lies in the comprehensive manufacturing of Vitamin D3. The Company maintains a sustainable supply chain, providing a notable advantage in the contemporary global market.

The company’s array of Vitamin D3 variants is finely balanced to meet the requirements of both human and animal nutrition, rendering them applicable across a broad spectrum of uses. In addition to Vitamin D3 products, the company engages in the production of APIs for muscle relaxants and anti-flatulent applications. The Company also pioneers the development of innovative enzymes crucial for manufacturing active pharmaceutical ingredients, alongside offering environmental solutions for wastewater treatment and management.

The strategic possession of legacy properties in Thane and Worli, Mumbai, serves as a lucrative source of income for the company. This supplementary revenue stream complements the core business activities, reinforcing the Company’s financial position. Through a development agreement with Mextech Property Developers LLP, the company is poised to construct residential-cum-commercial buildings on its free-hold Thane land and would acquire affordable luxury residential apartments from Mextech on an area sharing basis.

Furthermore, the company has undertaken sale transactions for its IT/ITES building, Thane One. As of the report date, the company has successfully divested a significant portion of the IT/ITES building to third parties. The proceeds from these transactions were judiciously utilized to retire outstanding loans associated with the IT/ITES building.

Business area of the company

The company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products and renting and selling of properties. The Company caters to both domestic and international markets. The company also has strategic investments in subsidiaries primarily dealing in manufacturing and marketing bulk drugs.

Business Segments

  • Vitamin D and niche APIs
  • Nutrition
  • Integrated biotechnology
  • Environment solutions
  • Real Estate

Awards

  • 2025: Pride of Maharashtra Award
  • 2024: Fi India Awards 
  • 2023: Excellence in Pharma Supply Chain Award
  • 2021: Indian Pharma Award
  • 2020: Business Leader of The Year Awards 
  • 2020: Hindustan Times Thane Ratna Award
  • 2019: Business Excellence Awards 
  • 2019: Hindustan Times Thane Ratna Award
  • 2018: Indian Pharma Award

Milestones/ History

  • 1951: Established International Franchises Private Ltd. to focus on the toll manufacturing of pharmaceutical products.
  • 1963: Formed joint venture with Philips Duphar SV
  • 1967: Commenced the commercial manufacture of Vitamin D
  • 1980: After Solvay acquired Philips Duphar SV, it became the new joint venture partner.
  • 1986: Established the company to manufacture enzymes used as catalyst in antibiotic manufacturing.
  • 2002: Demerged the pharmaceutical business to Solvay.
  • 2003: Consolidated all manufacturing at kullu by expanding the facility to include Vitamin D and other products.
  • 2011: Commenced the second plant for manufacturing Vitamin D at Dahej.
  • 2012: The company introduced its latest catalyst Fermase PA 850 for Penicillin G Acylase and enhanced the production capacity of Vitamin D resin in Dahej.
  • 2014: Launched Vitamin D 100 CWD to cater to the food and dietary nutraceutical supplements market.
  • 2016: Enhanced Vitamin D capacity at Dahej. Launched a new version of Vitamin D 500 feed grade powder.
  • 2017: Obtained EDQM’s CEP certification for its Vitamin D manufacturing facility in Dahej; and received FSSC 22000 and BRC food safety approvals for both plants.
  • 2019: Completed the amalgamation of DIL Limited and Fermenta Biotech Limited (combined entity was renamed as Fermenta Biotech Limited). Incorporated a wholly owned subsidiary called Fermenta Biotech GmbH in Germany. Integrated backwards to manufacture cholesterol, the key starting material of Vitamin D.
  • 2020: Introduced fish oil cholesterol for aquaculture nutrition. Established a wholly owned subsidiary named Fermenta Biotech USA LLC in the USA. Acquired a controlling stake in AGD Nutrition, a US-based vitamin company, through Fermenta Biotech USA LLC and renamed it as Fermenta USA LLC.
  • 2021: Launched Vitamin AD2 for oil fortification.
  • 2022: Signed a binding term sheet with Mextech Property Developers LLP for the development of a land parcel in Thane. Fermenta commissioned its fortified rice kernel manufacturing facility in Pennepalli, Andhra Pradesh.
  • 2023: Commissioned its customised food premixing plant in Kullu, Himachal Pradesh.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×